Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment

Pharmacogenetics and Genomics

Volumn 24, Issue 6, 2014, Pages 314-319

  Drago, Antonio ^d   Giegling, Ina ^a,b   Schäfer, Martin ^a   Hartmann, Annette M ^b   Konte, Bettina ^b   Friedl, Marion ^b   Serretti, Alessandro ^c   Rujescu, Dan ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

gene; haloperidol; schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; SPACER DNA;

ADULT; ARTICLE; AT RICH INTERACTIVE DOMAIN 5B GENE; CONTROLLED STUDY; EUKARYOTIC TRANSLATION INITIATION FACTOR 2ALPHA KINASE 4 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE MAP; HETEROZYGOSITY; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY CONTROL; RHOTEKIN 2 GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ALLELE; GENETICS; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE;

EUKARYOTA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HALOPERIDOL; HUMANS; IMMUNE SYSTEM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84900521403     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000052     Document Type: Article

References (30)

1. Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose forthe acute phase of schizophrenia. Cochrane Database Syst Rev 20023:CD001951.
2. Schäfer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, et al.Association of short-term response to haloperidol treatment with apolymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001158:802-804.
3. Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, et al.The-141C Ins/Del polymorphism in the dopamine D2 receptor genepromoter region is associated with anxiolytic and antidepressive effectsduring treatment with dopamine antagonists in schizophrenic patients.Pharmacogenetics 2001 11:545-550.
4. Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, et al. Homer-1polymorphisms are associated with psychopathology and response totreatment in schizophrenic patients. J Psychiatr Res 2011 45:234-241.
5. Giegling I, Drago A, Dolz?an V, Plesnic? ar BK, Schäfer M, Hartmann AM, et al.Glutamatergic gene variants impact the clinical profile of efficacyand side effects of haloperidol. Pharmacogenet Genomics 201121:206-216.
6. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, et al. Effects of theCYP2D6 genotype on the steady-state plasma concentrations of haloperidoland reduced haloperidol in Japanese schizophrenic patients.Pharmacogenetics 1997 7:415-418.
7. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, et al.Genome-wide pharmacogenomic analysis of response to treatment withantipsychotics. Mol Psychiatry 2011 16:76-85.
8. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, et al.Association of the NPAS3 gene and five other loci with response to theantipsychotic iloperidone identified in a whole genome association study.Mol Psychiatry 2009 14:804-819.
9. Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, et al.Identification of novel candidate genes for treatment response to risperidoneand susceptibility for schizophrenia: integrated analysis amongpharmacogenomics, mouse expression, and genetic case-controlassociation approaches. Biol Psychiatry 2010 67:263-269.
10. Giegling I, Drago A, Schäfer M, Möller H-J, Rujescu D, Serretti A.Sociodemographic and treatment related variables are poor predictors ofhaloperidol induced motor side effects. Prog Neuropsychopharmacol BiolPsychiatry 2011 35:74-77.
11. Giegling I, Drago A, Schäfer M, Möller H-J, Rujescu D, Serretti A. Interactionof haloperidol plasma level and antipsychotic effect in early phases of acutepsychosis treatment. J Psychiatr Res 2010 44:487-492.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale(PANSS) for schizophrenia. Schizophr Bull 1987 13:261-276.
13. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G.Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal SymptomRating Scale (ESRS): cross-scale comparison in assessing tardivedyskinesia. Schizophr Res 2005 77:119-128.
14. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE,et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv2008 59:500-506.
15. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. TheNational Institute of Mental Health Clinical Antipsychotic Trials ofIntervention Effectiveness (CATIE) project: schizophrenia trial design andprotocol development. Schizophr Bull 2003 29:15-31.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al.PLINK: a tool set for whole-genome association and population-basedlinkage analyses. Am J Hum Genet 2007 81:559-575.
17. Cichon S, Mühleisen TW, Degenhardt FA, Mattheisen M, Miró X, Strohmaier J,et al. Genome-wide association study identifies genetic variation in neurocanas a susceptibility factor for bipolar disorder. Am J Hum Genet 201188:372-381.
18. Ferentinos P, Dikeos D. Genetic correlates of medical comorbidityassociated with schizophrenia and treatment with antipsychotics. Curr OpinPsychiatry 2012 25:381-390.
19. Gilvarry CM, Sham PC, Jones PB, Cannon M, Wright P, Lewis SW, et al.Family history of autoimmune diseases in psychosis. Schizophr Res 199619:33-40.
20. Gorwood P, Pouchot J, Vinceneux P, Pué chal X, Flipo RM, De Bandt M, et al.Rheumatoid arthritis and schizophrenia: a negative association at adimensional level. Schizophr Res 2004 66:21-29.
21. Oken RJ, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: thenegative association revisited. Schizophr Bull 1999 25:625-638.
22. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. Commonvariants on chromosome 6p22.1 are associated with schizophrenia. Nature2009 460:753-757.
23. International Schizophrenia Consortium. Rare chromosomal deletions andduplications increase risk of schizophrenia. Nature 2008 455:237-241.
24. Sun Z-Y,Wei J, Xie L, Shen Y, Liu S-Z, Ju G-Z, et al. The CLDN5 locus maybe involved in the vulnerability to schizophrenia. Eur Psychiatry 200419:354-357.
25. Guilloux J-P, Gaiteri C, Sibille E. Network analysis of positional candidategenes of schizophrenia highlightsymore thanymyelin-related pathways.Mol Psychiatry 2010 15:786-788.
26. Sullivan PF. Spurious genetic associations. Biol Psychiatry 200761:1121-1126.
27. Berlanga JJ, Santoyo J, De Haro C. Characterization of a mammalianhomolog of the GCN2 eukaryotic initiation factor 2alpha kinase. Eur JBiochem 1999 265:754-762.
28. St Clair D, Blackwood D, Muir W, Carothers A,Walker M, Spowart G, et al.Association within a family of a balanced autosomal translocation with majormental illness. Lancet 1990 336:13-16.
29. Matsuzaki S, Tohyama M. Molecular mechanism of schizophrenia withreference to disrupted-in-schizophrenia 1 (DISC1). Neurochem Int 200751:165-172.
30. Lin P-I, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: theflip-flop phenomenon. Am J Hum Genet 2007 80:531-538.